M. Fukuoka, Y. L. Wu, S. Thongprasert, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/ paclitaxel in clinically selected patients with advanced non- small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology, 2011, 29(21): 2866-2874.